Around half of people will experience a mental health issue in their lifetime

A 2023 analysis of World Mental Health Survey data from more than 150,000 people across 29 countries estimates that 46% of men and 53% of women will experience at least one of 13 studied mental disorders by age 75. The article estimates that for the 11 disorders it covers, at least 40% of men and 48% of women—and likely figures closer to the 13-disorder estimates—will experience one by age 75. Depression and anxiety are more common among women, while substance-use disorders are more common among men; bipolar disorder rates are similar.

Analysis

This is a structural demand signal, not a near-term earnings catalyst. Lifetime prevalence does not establish how many people are currently seeking care, diagnosed, insured, or able to access treatment. The monetizable pool is therefore narrower than the headline suggests—and constrained by clinician capacity, reimbursement, and willingness to pay.

Over 6–18 months, the more plausible beneficiaries are providers that can add capacity at attractive unit economics, including telebehavioral-health platforms and scaled outpatient networks. Employers may also expand EAP and virtual-care coverage to address absenteeism and retention. But higher utilization can be a cost headwind for insurers and self-insured employers; it is not automatically favorable to them. Drug makers are a weaker read-through: broad lifetime prevalence does not specify treatment rates or imply meaningful incremental sales, particularly for conditions often treated with generics.

The contrarian point is that the statistic may be more useful as evidence of an access and capacity gap than as evidence of a large addressable market. Survey-based lifetime estimates across countries and decades are not a direct measure of current U.S. demand, and improved recognition can raise diagnosed utilization without a comparable change in underlying incidence. No trade is warranted on this article alone. A reversal in the investment thesis would be evidence that reimbursement, clinician supply, or patient engagement prevents prevalence from converting into paid visits.

Key Decisions for Investors

• No immediate position: treat the study as background evidence, not a revenue or earnings revision catalyst.
• Watch public behavioral-health providers and virtual-care platforms for reported paid visits, clinician utilization, retention, and contribution economics; do not infer growth from prevalence alone.
• Monitor insurer and employer disclosures for behavioral-health utilization and claims-cost trends. Rising utilization without offsetting productivity or retention benefits would be a potential margin headwind.
• Revisit the theme only if coverage or reimbursement expands and providers demonstrate capacity growth without deteriorating unit economics; the thesis weakens if access constraints persist or paid engagement remains low.